Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94110


To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance spectroscopy.


Inclusion Criteria Patients must have: - Biopsy-proven Kaposi's sarcoma (KS) with multiple cutaneous lesions. - Minimum life expectancy of 3 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Clinically significant cardiac disease. - Known hemorrhagic diathesis or active bleeding disorder. - Clinically apparent vascular disease. - Known lipoprotein disorders. - History of seizure disorder or central nervous system (CNS) metastasis. - Additional malignancy. Concurrent Medication: Excluded: - Cardiac agents. - Anticoagulants. - Thrombolytic agents. - Nonsteroidal anti-inflammatory drugs. - Corticosteroids. - Aspirin. - Vasodilators. Patients with the following are excluded: - Additional malignancies or other conditions listed in Patient Exclusion Co-Existing Conditions. Prior Treatment: Excluded within 4 weeks of study entry: - Chemotherapy. - Radiotherapy. - Immunotherapy.



Primary Contact:


Backup Contact:


Location Contact:

San Francisco, California 94110
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.